UpcomingPDUFA target action date

Anito-cel (anitocabtagene autoleucel)

Gilead Sciences (Arcellx) (GILD)

Marketer take

A new CAR-T entrant in late-line myeloma, where treatment-center onboarding and referral pathways matter more than broad HCP reach.

Sponsor company
Gilead Sciences (Arcellx) (GILD)
Indication
Relapsed/refractory multiple myeloma, 4th line and later
Therapeutic area
Oncology, Hematology
Event
PDUFA target action date
Date
Dec 23, 2026
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move